Inovio To Start Global Late-Stage COVID-19 Vaccine Trial

  • The regulatory authority of Brazil has signed off Inovio Pharmaceuticals Inc's INO global Phase 3 segment of its INNOVATE Phase 2/3 trial for INO-4800, DNA COVID-19 vaccine candidate.
  • Related Content: Inovio's DNA COVID-19 Vaccine Candidate Triggers Immune Response In Pivotal Study.
  • Inovio plans to conduct the global Phase 3 segment in multiple countries, including Brazil, with partner Advaccine Biopharmaceuticals Suzhou Co Ltd.
  • Phase 3 will evaluate the efficacy of INO-4800 in a two-dose regimen (2.0 mg per dose), administered one month apart. 
  • The primary endpoint of the trial is virologically confirmed COVID-19.
  • Also Read: Inovio's Pan-COVID-19 Vaccine Candidate Can Provide Immune Responses Against Variants.
  • Earlier this month, China signed off two clinical trials for heterologous boosting with INO-4800 through Advaccine as the trial sponsor. 
  • Working with Sinovac Biotech Ltd SVA, Advaccine will evaluate the heterologous prime-boost sequential immunizations using INO-4800 and CoronaVac.
  • Related content: Benzinga's Full FDA Calendar.
  • Price Action: INO shares are up 9.47% at $9.23 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLong IdeasNewsHealth CareFDAMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusCOVID-19 VaccinePhase 3 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!